StrengthSpan Wisdom
Growth hormone treatment had finally become possible.
But there was a remarkable limitation.
Every dose of human growth hormone depended on pituitary glands collected after death.
The treatment could help children with severe GH deficiency grow—but the supply was scarce.
Then another field of science began changing what was possible.
Scientists learned to use genetic instructions to produce human proteins.
By 1979, recombinant human growth hormone had been produced.
And then came 1985.
Young adults who had received pituitary-derived GH years earlier developed Creutzfeldt-Jakob disease.
The old source was withdrawn.
But another source was already approaching clinical use.
In October 1985, the FDA approved Protropin, a recombinant growth hormone product.
A scarce human extract was becoming a manufactured medicine.
Growth hormone had entered a new era.
StrengthSpan — The History of Growth Hormone, Part 4
When Growth Hormone Entered a New Era
👇 Next Sunday — Part 5
With recombinant GH now available, scientists could investigate the hormone in ways that had never been possible before.
Adaptation is Survival.
#GrowthHormone #HumanGrowthHormone #Endocrinology #Biotechnology #MedicalHistory #ScienceHistory #StrengthSpan #AdaptationIsSurvival #WriteToRewire
The evolution of growth hormone therapy is not only a fascinating chapter in medical history but also a powerful example of how biotechnology can overcome natural limitations to improve patient outcomes. Initially, the reliance on human pituitary glands collected after death posed severe supply constraints and safety concerns, particularly highlighted by the emergence of Creutzfeldt-Jakob disease among recipients of pituitary-derived hormone. With recombinant DNA technology, scientists didn't just find a new source—they unlocked a scalable approach that enabled mass production of human growth hormone without depending on scarce human tissue. The approval of Protropin by the FDA in 1985 marked the arrival of biotechnologically manufactured medicines into mainstream clinical use, setting the stage for more accessible and safer hormone therapies. From personal observations within the endocrinology field, this shift profoundly expanded treatment possibilities. Patients who once faced long waiting lists due to limited hormone availability began experiencing timely interventions that drastically improved growth outcomes and quality of life. Moreover, recombinant production allowed researchers to explore various dosing regimens and treatment protocols previously unimaginable when supplies were scarce. This case illustrates the broader impact of genetic engineering in medicine, where understanding and utilizing genetic instructions enable the production of complex proteins vital for health. It demonstrates how adapting to new scientific methods ensures survival and advancement in therapeutic approaches—truly a testament to innovation overcoming adversity. Reflecting on this history, it’s clear that the recombinant production of growth hormone didn't just solve a supply problem but ushered in a new era of medical biotechnology, profoundly influencing treatment strategies and ongoing research in endocrinology and beyond. For anyone interested in medical history or biotechnology, this milestone is a compelling example of how science continually adapts to meet human health needs.
